Sagimet Biosciences Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Revenue | — | — | $2.0M | — |
| Operating income | -$56.9M | -$54.5M | -$30.7M | -$31.1M |
| Operating expenses | $56.9M | $54.5M | $32.7M | $31.1M |
| Cash from operations | -$45.6M | -$42.4M | -$23.8M | -$24.5M |
| Total assets | $116.5M | $160.3M | $96.7M | $33.0M |
| Total liabilities | — | — | $5.7M | $5.4M |
Shares outstanding 61.8M · Free float 72.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.